![Documents Document Submission](/images/default-source/default-album/document-review/documents.jpg?sfvrsn=d9b80dc1_1)
Rate This Document
A Response to FDA Perspective on Approaches for Complying with CGMPS During Phase I INDs Draft Guidance for Industry
- Description: by Barry Friedman, PhD, Director, Quality Control, Cambrex Bio Science-Baltimore
- Published on: Nov 16, 2023
- Rating Period:
Your rating for this document has already been submitted